Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to a vaccination regimen evaluated in a Phase IV clinical trial (NCT03332732) led by the Centers for Disease Control and Prevention (CDC). The regimen consists of the standard Inactivated Poliovirus Vaccine (IPV), a fractional dose of the Inactivated Poliovirus Vaccine (fIPV) delivered intradermally as a booster, and the Rotarix rotavirus vaccine. IPV and fIPV provide active immunity against poliomyelitis by inducing neutralizing antibodies to poliovirus types 1, 2, and 3. Rotarix is a live-attenuated monovalent human rotavirus vaccine (strain RIX4414) designed to prevent gastroenteritis caused by rotavirus. The study specifically investigates the immunogenicity and optimization of polio vaccination schedules, including dose-sparing fractional doses, when administered concomitantly with rotavirus vaccines in infants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactivated poliovirus vaccine + fractional inactivated poliovirus vaccine + Rotarix.